Skip to main content
OpenTrials
Completed

NCT Number: NCT00918814

Dose Ranging and Dose Frequency of LIPO-102

Dose Ranging and Dose Frequency of LIPO-102

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Subcutaneous Adipose Tissue Reduction

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

San Diego, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or non pregnant female
  • Good general health
  • Sufficient abdominal fat for injections
  • Signed informed consent

Exclusion criteria

  • Known hypersensitivity to study drugs
  • Treatment with an investigational agent within 30 days of first dose

Treatment and study plan

LIPO-102

Drug

Subcutaneous Injection

Placebo

Drug

Placebo

Primary outcomes

  1. Safety: physical examinations, laboratory tests, AE assessment

    Time frame: 4 weeks treatment and 4 weeks follow up

Secondary outcomes

  1. Efficacy: change in subcutaneous abdominal adipose tissue thickness

    Time frame: 4 weeks treatment and 4 weeks follow up

Sponsors and collaborators

Lead sponsor

Neothetics, Inc

Industry

Registry information

Official study title

A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Jun 11, 2009
Registry last updated
Mar 6, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.